MCID: CHR283
MIFTS: 51

Chronic Inflammatory Demyelinating Polyneuropathy

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Chronic Inflammatory Demyelinating Polyneuropathy

MalaCards integrated aliases for Chronic Inflammatory Demyelinating Polyneuropathy:

Name: Chronic Inflammatory Demyelinating Polyneuropathy 37 72 49 50 55
Chronic Inflammatory Demyelinating Polyradiculoneuropathy 49 55
Cidp 49 55
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 69

Characteristics:

Orphanet epidemiological data:

55
chronic inflammatory demyelinating polyneuropathy
Inheritance: Not applicable; Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy;

Classifications:

Orphanet: 55  
Rare neurological diseases


External Ids:

Orphanet 55 ORPHA2932
UMLS via Orphanet 70 C0393819
ICD10 via Orphanet 33 G61.8

Summaries for Chronic Inflammatory Demyelinating Polyneuropathy

NIH Rare Diseases : 49 Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder that causes progressive weakness and impaired sensory function in the legs and arms. Symptoms often include tingling or numbness (first in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes, fatigue, and abnormal sensations. CIDP is thought to be caused by the immune system mistakenly attacking and damaging the myelin sheath (protective cover of nerve fibers) of the peripheral nerves. CIDP is closely related to Guillain-Barre syndrome (GBS) and is considered the "chronic counterpart" of GBS. Treatment may include corticosteroids, immunosuppressant drugs, plasma exchange, physical therapy, and/or intravenous immunoglobulin (IVIG) therapy. Left untreated, 30% of people with CIDP will progress to wheelchair dependence. Last updated: 2/27/2017

MalaCards based summary : Chronic Inflammatory Demyelinating Polyneuropathy, also known as chronic inflammatory demyelinating polyradiculoneuropathy, is related to demyelinating polyneuropathy and pulmonary tuberculosis, and has symptoms including areflexia, unsteady gait and paresthesia. An important gene associated with Chronic Inflammatory Demyelinating Polyneuropathy is AIF1 (Allograft Inflammatory Factor 1), and among its related pathways/superpathways are L1CAM interactions and Cell adhesion molecules (CAMs). The drugs Antibodies and gamma-Globulins have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and skin.

NINDS : 50 Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disorder, which is sometimes called chronic relapsing polyneuropathy, is caused by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibers) of the peripheral nerves. Although it can occur at any age and in both genders, CIDP is more common in young adults, and in men more so than women. It often presents with symptoms that include tingling or numbness (beginning in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes (areflexia), fatigue, and abnormal sensations. CIDP is closely related to Guillain-Barre syndrome and it is considered the chronic counterpart of that acute disease.

Wikipedia : 72 Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated inflammatory... more...

Related Diseases for Chronic Inflammatory Demyelinating Polyneuropathy

Diseases in the Demyelinating Polyneuropathy family:

Chronic Inflammatory Demyelinating Polyneuropathy Subacute Inflammatory Demyelinating Polyneuropathy

Diseases related to Chronic Inflammatory Demyelinating Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 133)
# Related Disease Score Top Affiliating Genes
1 demyelinating polyneuropathy 29.8 AIF1 CNTN2 HP NFASC TTR
2 pulmonary tuberculosis 29.3 HLA-DRB1 HP
3 chronic inflammatory demyelinating polyradiculoneuropathy 12.6
4 chronic inflammatory demyelinating polyneuritis 11.3
5 polyneuropathy 11.2
6 polyradiculoneuropathy 11.2
7 guillain-barre syndrome, familial 10.9
8 neuropathy 10.6
9 hepatitis 10.3
10 myasthenia gravis 10.3
11 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.3
12 charcot-marie-tooth disease 10.3
13 diabetes mellitus 10.3
14 tooth disease 10.3
15 myasthenia gravis congenital 10.3
16 multiple sclerosis 10.2
17 poems syndrome 10.2
18 melanoma 10.2
19 hepatitis b 10.2
20 multifocal motor neuropathy 10.2
21 lymphoma 10.2
22 lupus erythematosus 10.2
23 systemic lupus erythematosus 10.1
24 episodic pain syndrome, familial, 1 10.1
25 glomerulonephritis 10.1
26 respiratory failure 10.1
27 carpal tunnel syndrome 10.0
28 charcot-marie-tooth disease, demyelinating, type 1a 10.0
29 focal segmental glomerulosclerosis 1 10.0
30 mycobacterium tuberculosis 1 10.0
31 mononeuropathy of the median nerve, mild 10.0
32 membranous nephropathy 10.0
33 arthritis 10.0
34 crohn's disease 10.0
35 diabetic neuropathy 10.0
36 focal segmental glomerulosclerosis 10.0
37 scoliosis 10.0
38 abducens nerve disease 10.0
39 diabetic polyneuropathy 10.0
40 guillain-barre syndrome 10.0
41 mononeuritis multiplex 10.0
42 hepatitis c 10.0
43 myopathy 10.0
44 pustulosis of palm and sole 10.0
45 neuronitis 10.0
46 psoriasis 10.0
47 intracranial hypertension 10.0
48 amyloid neuropathy 10.0
49 endotheliitis 10.0
50 amyotrophic lateral sclerosis 1 9.9

Graphical network of the top 20 diseases related to Chronic Inflammatory Demyelinating Polyneuropathy:



Diseases related to Chronic Inflammatory Demyelinating Polyneuropathy

Symptoms & Phenotypes for Chronic Inflammatory Demyelinating Polyneuropathy

Human phenotypes related to Chronic Inflammatory Demyelinating Polyneuropathy:

55 31 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 areflexia 55 31 hallmark (90%) Very frequent (99-80%) HP:0001284
2 unsteady gait 55 31 hallmark (90%) Very frequent (99-80%) HP:0002317
3 paresthesia 55 31 hallmark (90%) Very frequent (99-80%) HP:0003401
4 segmental peripheral demyelination/remyelination 55 31 hallmark (90%) Very frequent (99-80%) HP:0003481
5 sensory ataxia 55 31 hallmark (90%) Very frequent (99-80%) HP:0010871
6 motor conduction block 55 31 hallmark (90%) Very frequent (99-80%) HP:0012078
7 fatiguable weakness of proximal limb muscles 55 31 hallmark (90%) Very frequent (99-80%) HP:0030200
8 difficulty walking 55 31 frequent (33%) Frequent (79-30%) HP:0002355
9 falls 55 31 frequent (33%) Frequent (79-30%) HP:0002527
10 difficulty climbing stairs 55 31 frequent (33%) Frequent (79-30%) HP:0003551
11 hand muscle weakness 55 31 frequent (33%) Frequent (79-30%) HP:0030237
12 spontaneous pain sensation 55 31 occasional (7.5%) Occasional (29-5%) HP:0010833
13 decreased nerve conduction velocity 55 Very frequent (99-80%)
14 sensory impairment 55 Very frequent (99-80%)
15 peripheral neuropathy 55 Very frequent (99-80%)
16 peripheral demyelination 55 Very frequent (99-80%)
17 abnormal nerve conduction velocity 55 Very frequent (99-80%)

Drugs & Therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy

Drugs for Chronic Inflammatory Demyelinating Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
2 gamma-Globulins Phase 4,Phase 3,Phase 2
3 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
4 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2
5 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2
6
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
7
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
8
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
9 tannic acid Approved, Nutraceutical Phase 3
10 Fingolimod Hydrochloride Phase 3
11 Immunosuppressive Agents Phase 3,Phase 2
12 Anti-Inflammatory Agents Phase 3
13 Antineoplastic Agents, Hormonal Phase 3
14 glucocorticoids Phase 3
15 Hormone Antagonists Phase 3,Phase 2
16 Hormones Phase 3,Phase 2
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
18 Pharmaceutical Solutions Phase 3,Phase 2
19
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
21 Antioxidants Phase 2
22 Micronutrients Phase 2
23 Protective Agents Phase 2
24 Thioctic Acid Phase 2
25 Trace Elements Phase 2
26 Vitamin B Complex Phase 2
27 Vitamins Phase 2
28 Adjuvants, Immunologic Phase 2
29 Anti-Infective Agents Phase 2
30 Antiviral Agents Phase 2
31 Interferon-beta Phase 2
32 interferons Phase 2
33 Alpha-lipoic Acid Nutraceutical Phase 2
34 Folate Nutraceutical Phase 2
35 Vitamin B9 Nutraceutical Phase 2

Interventional clinical trials:

(show all 42)

# Name Status NCT ID Phase Drugs
1 IVIg for Demyelination in Diabetes Mellitus Recruiting NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
3 Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
4 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
5 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01184846 Phase 3
6 Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Completed NCT01625182 Phase 3 Fingolimod;Placebo Comparator
7 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed NCT01545076 Phase 3
8 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
9 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
10 Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
11 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
12 Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Completed NCT02293460 Phase 3 I10E
13 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
14 Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP Recruiting NCT02955355 Phase 3
15 Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP Recruiting NCT02549170 Phase 3
16 Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy Recruiting NCT02638207 Phase 3 NewGam
17 Panzyga in CIDP Administered at Different Infusion Rates Not yet recruiting NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
18 Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Terminated NCT02317562 Phase 3 I10E
19 Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP Terminated NCT01225276 Phase 2, Phase 3 NewGam 10%;Placebo;NewGam 10%;NewGam 10%
20 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00962429 Phase 2 lipoic acid
21 Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2 Interferon Beta-1a
22 Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
23 Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01017159 Phase 2 Subcutaneous immunoglobulin
24 Stem Cell Transplantation for Stiff Person Syndrome (SPS) Recruiting NCT02282514 Phase 1, Phase 2
25 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Recruiting NCT02967679 Phase 1, Phase 2 MD1003
26 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Active, not recruiting NCT00278629 Phase 2
27 High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
28 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
29 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT01379833
30 sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN Unknown status NCT02271724
31 Effect of Resistance and Aerobic Exercise in CIDP or MMN Completed NCT02121678
32 MRI in Diagnosing and Monitoring CIDP Completed NCT02017769
33 Study of CIDP Patients During IVIG Treatment Completed NCT00305266 intravenous gammaglobulin
34 Immunoglobulin Dosage and Administration Form in CIDP and MMN Completed NCT02111590 Immunoglobulins
35 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
36 IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements Recruiting NCT02414490 Intravenous Immunoglobulin
37 Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Recruiting NCT02629796
38 Transcriptome Analysis of the Peripheral Blood in CIDP Recruiting NCT02404298 IVIg
39 Early Diagnosis of TTR Amyloidosis by Use of Molecular Biology Recruiting NCT03373370
40 Subcutaneous Immunoglobulin for CIDP Active, not recruiting NCT02465359 Immune Globulin Subcutaneous (Human)
41 Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin Not yet recruiting NCT02892890
42 Quantification of Nerve Stiffness in Neuropathies Not yet recruiting NCT03397303

Search NIH Clinical Center for Chronic Inflammatory Demyelinating Polyneuropathy

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Chronic Inflammatory Demyelinating Polyneuropathy:
Hematopoietic stem cells for treatment of chronic inflammatory demyelinating polyneuropathy
Embryonic/Adult Cultured Cells Related to Chronic Inflammatory Demyelinating Polyneuropathy:
Bone marrow-derived hematopoietic stem cells PMIDs: 17277794

Genetic Tests for Chronic Inflammatory Demyelinating Polyneuropathy

Anatomical Context for Chronic Inflammatory Demyelinating Polyneuropathy

MalaCards organs/tissues related to Chronic Inflammatory Demyelinating Polyneuropathy:

38
T Cells, Bone, Skin, Spinal Cord, Endothelial, B Cells, Thyroid

Publications for Chronic Inflammatory Demyelinating Polyneuropathy

Articles related to Chronic Inflammatory Demyelinating Polyneuropathy:

(show top 50) (show all 555)
# Title Authors Year
1
Bilateral facial nerve palsies secondary to chronic inflammatory demyelinating polyneuropathy following adalimumab treatment. ( 29179036 )
2018
2
Cerebrospinal Fluid Cytokine Expression Profile in Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy. ( 29182448 )
2018
3
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. ( 29122523 )
2018
4
Elevated leukocyte count in cerebrospinal fluid of patients with chronic inflammatory demyelinating polyneuropathy. ( 29341326 )
2018
5
Elevated serum levels of endothelin-1 in patients with chronic inflammatory demyelinating polyneuropathy. ( 29137897 )
2018
6
Outcome in chronic inflammatory demyelinating polyneuropathy from a Malaysian centre over sixteen years. ( 29398193 )
2018
7
Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy. ( 29122522 )
2018
8
Vestibular impairment in chronic inflammatory demyelinating polyneuropathy. ( 29260355 )
2018
9
Myasthenia gravis and chronic inflammatory demyelinating polyneuropathy in the same patientA -A a case report. ( 29073825 )
2017
10
Unconventional treatments for chronic inflammatory demyelinating polyneuropathy. ( 29043889 )
2017
11
Chronic inflammatory demyelinating polyneuropathy. ( 28763304 )
2017
12
Chronic Inflammatory Demyelinating Polyneuropathy Variant with Creatine-Kinase Elevation and Vanishing Effect of Immunoglobulins. ( 28747620 )
2017
13
A prospective study comparing tryptophan immunoadsorption with therapeutic plasma exchange for the treatment of chronic inflammatory demyelinating polyneuropathy. ( 28485075 )
2017
14
Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with antineurofascin-155 and anticontactin-1 antibodies. ( 28073817 )
2017
15
Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial. ( 28768822 )
2017
16
Changes in spatiotemporal gait parameters following intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy. ( 28085193 )
2017
17
Chronic Inflammatory Demyelinating Polyneuropathy: A Case Series. ( 29143254 )
2017
18
ELectron microscopic abnormality and therapeutic efficacy in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin155 immunoglobulin G4 antibody. ( 28796305 )
2017
19
Electrodiagnostic errors contribute to chronic inflammatory demyelinating polyneuropathy misdiagnosis. ( 29053880 )
2017
20
The Prevalence and Severity of Autonomic Dysfunction in Chronic Inflammatory Demyelinating Polyneuropathy. ( 28904461 )
2017
21
Chronic inflammatory demyelinating polyneuropathy and malignancy: A systematic review. ( 29194677 )
2017
22
Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study. ( 28000311 )
2017
23
Utility of Neurological Imaging in Sensory Variant of Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report. ( 28221307 )
2017
24
Electrodiagnostic misdiagnosis of chronic inflammatory demyelinating polyneuropathy: What are the problems? and how to right the wrongs. ( 29193155 )
2017
25
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): An Uncommon Manifestation of Systemic Lupus Erythematosus (SLE). ( 28894082 )
2017
26
Nodopathy: chronic inflammatory demyelinating polyneuropathy with anti-neurofascin 155 antibodies. ( 28108521 )
2017
27
Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy: Diagnostic Accuracy and Correlation With Electrophysiology. ( 28574858 )
2017
28
Quantitative muscle ultrasound is useful for evaluating secondary axonal degeneration in chronic inflammatory demyelinating polyneuropathy. ( 29075571 )
2017
29
Anti-Ma2-associated limbic encephalitis with coexisting chronic inflammatory demyelinating polyneuropathy in a patient with non-Hodgkin lymphoma: A case report. ( 28984777 )
2017
30
Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. ( 28575198 )
2017
31
Resistance training and aerobic training improve muscle strength and aerobic capacity in chronic inflammatory demyelinating polyneuropathy. ( 28345260 )
2017
32
Charcot-Marie-Tooth disease type 2 caused by homozygous MME gene mutation superimposed by chronic inflammatory demyelinating polyneuropathy. ( 28855494 )
2017
33
Neuromuscular ultrasound findings in distal acquired demyelinating symmetric variant of chronic inflammatory demyelinating polyneuropathy. ( 28667663 )
2017
34
Acute-onset chronic inflammatory demyelinating polyneuropathy after Zika virus infection. ( 29175895 )
2017
35
Drug-induced cutaneous lupus erythematosus after immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a case series. ( 28480635 )
2017
36
Lumbar plexus in patients with chronic inflammatory demyelinating polyneuropathy: Evaluation with 3D nerve-sheath signal increased with inked rest-tissue rapid acquisition of relaxation enhancement imaging (3D SHINKEI). ( 28668438 )
2017
37
Postural tremor and chronic inflammatory demyelinating polyneuropathy. ( 27421831 )
2016
38
Acute-onset chronic inflammatory demyelinating polyneuropathy in hantavirus and hepatitis B virus coinfection: A case report. ( 27930572 )
2016
39
Evaluation of Patients with Refractory Chronic Inflammatory Demyelinating Polyneuropathy. ( 27463215 )
2016
40
Poster 353 Acute Onset Chronic Inflammatory Demyelinating Polyneuropathy (A-CIDP) with CNS Involvement Initially Diagnosed as Guillain-Barre Syndrome (GBS): A Case Report. ( 27673107 )
2016
41
Challenges in pediatric chronic inflammatory demyelinating polyneuropathy. ( 27793469 )
2016
42
Poster 487 Chronic Inflammatory Demyelinating Polyneuropathy or Something Else?: A Case Report. ( 27673228 )
2016
43
The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. ( 27389526 )
2016
44
Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. ( 27401495 )
2016
45
Diffusion tensor imaging can be used to detect lesions in peripheral nerves in patients with chronic inflammatory demyelinating polyneuropathy treated with subcutaneous immunoglobulin. ( 27114080 )
2016
46
Intrathecal Dexmedetomidine for Anaesthetic Management of a Patient with Chronic Inflammatory Demyelinating Polyneuropathy. ( 27790558 )
2016
47
Paranodal lesions in chronic inflammatory demyelinating polyneuropathy associated with anti-Neurofascin 155 antibodies. ( 27986399 )
2016
48
The development of chronic inflammatory demyelinating polyneuropathy during adalimumab treatment in a patient with psoriasis vulgaris. ( 27086491 )
2016
49
NADPH oxidase 2 (NOX2) enzyme activation in patients with chronic inflammatory demyelinating polyneuropathy. ( 26924156 )
2016
50
Poster 11 A Rare Case of Chronic Inflammatory Demyelinating Polyneuropathy in the Setting of SLE: A Case Report. ( 27672778 )
2016

Variations for Chronic Inflammatory Demyelinating Polyneuropathy

Expression for Chronic Inflammatory Demyelinating Polyneuropathy

Search GEO for disease gene expression data for Chronic Inflammatory Demyelinating Polyneuropathy.

Pathways for Chronic Inflammatory Demyelinating Polyneuropathy

Pathways related to Chronic Inflammatory Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.05 CNTN2 NFASC
2 10.96 CNTN2 HLA-DRB1 NFASC

GO Terms for Chronic Inflammatory Demyelinating Polyneuropathy

Cellular components related to Chronic Inflammatory Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 8.96 CNTN2 NFASC
2 node of Ranvier GO:0033268 8.62 CNTN2 NFASC

Biological processes related to Chronic Inflammatory Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon guidance GO:0007411 9.16 CNTN2 NFASC
2 neutrophil degranulation GO:0043312 9.13 HP NFASC TTR
3 protein localization to juxtaparanode region of axon GO:0071205 8.62 CNTN2 NFASC

Sources for Chronic Inflammatory Demyelinating Polyneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....